Even after a plunge last month that wiped US$46 billion off Chinese healthcare stocks, domestic drugmakers might be far from their floor as a Beijing-led policy shift gathers pace.
China’s plan to drive down generic drug prices through a centralized bulk procurement program is set to redraw the industry by forcing its thousands of small generic drugmakers to streamline and consolidate after decades of enjoying outsized profit margins.
“There won’t be a second act for traditional generic drugmakers in China,” said Dai Ming (戴明), Shanghai-based fund manager at Hengsheng Asset Management Co (恒盛資產管理)
Photo: Reuters
“In the past, there was hope that these companies would benefit from more government investment in healthcare due to the aging population, but now these healthcare stocks will be further hurt by policy and undergo a greater correction,” Dai said.
To survive the shifting landscape and rely less on generics — drugs whose patents have expired — many companies are scrambling to pump money into research and development (R&D).
Discovering a new medicine allows companies to earn high profits for as long as the new drug is covered by a patent, balancing out the loss of revenue from the fall in generic drug prices.
Chinese companies had been in a sweet spot.
Among the top 100 generic drugmakers, Chinese firms had a 74 percent gross margin and an 18 percent profit margin in the third quarter of last year, compared with a global average of 55 percent and 9.5 percent respectively, according to data compiled by Bloomberg.
The privileged position was due to the quirks of China’s regulatory system. While multinational giants had to wait years for approval to import their new drugs, the domestic generic makers could do a thriving business in copying, testing and getting local permission for the medicines.
At the same time, the industry benefited because of the lack of a centralized system for quality control.
Multinationals like Pfizer Inc and AstraZeneca PLC could win more hospital tenders for their off-patent drugs, as they could more easily offer quality assurances for their higher-cost medicines. That kept prices elevated throughout the pharma sector.
Now, China has embarked on a pilot program in which major cities buy certain drugs in bulk, forcing companies to bid for contracts and driving prices down by an average of 52 percent, one by as much as 90 percent.
Chinese Vice Premier Sun Chunlan (孫春蘭) last week said that China would be expanding the program to cover more cities and drugs, as medicine prices must fall for healthcare to be affordable for the public.
Chinese companies that are already heavily invested in R&D stand the best chance of surviving the new landscape.
Among firms listed in China, Jiangsu Hengrui Medicine Co (恆瑞醫藥) has invested the most in research by far — amounting to 16 percent of revenue in the latest quarter. Guangzhou-based Yipinhong Pharmaceutical Co (一品紅藥業) is in second place with 8.4 percent. Zhejiang Jingxin Pharmaceutical Co (京新藥業), Chengdu Kanghong Pharmaceutical Group Co (康弘藥業) and Tianjin Lisheng Pharmaceutical Co (天津力生製藥) have each invested about 8 percent of sales into research.
Among Hong Kong-traded shares, CSPC Pharmaceutical Group Ltd (石藥集團) has 8.14 percent of sales invested in research and Sino Biopharmaceutical Ltd (中國生物製藥) has 6.23 percent.
Jiangsu Hengrui gets 20 percent of its revenue from novel drugs and 80 percent from generics, a ratio it wants to flip, Lianshan Zhang, president of global R&D, said in an interview last month.
However, a successful novel drug can take decades to develop, and the Chinese pharmaceuticals are up against the deep pockets and research talent of the multinationals, which are enjoying rapid approval from Chinese regulators for their new medicine.
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
ARTIFICIAL INTELLIGENCE: The chipmaker last month raised its capital spending by 28 percent for this year to NT$32 billion from a previous estimate of NT$25 billion Contract chipmaker Powerchip Semiconductor Manufacturing Corp (力積電子) yesterday launched a new 12-inch fab, tapping into advanced chip-on-wafer-on-substrate (CoWoS) packaging technology to support rising demand for artificial intelligence (AI) devices. Powerchip is to offer interposers, one of three parts in CoWoS packaging technology, with shipments scheduled for the second half of this year, Powerchip chairman Frank Huang (黃崇仁) told reporters on the sidelines of a fab inauguration ceremony in the Tongluo Science Park (銅鑼科學園區) in Miaoli County yesterday. “We are working with customers to supply CoWoS-related business, utilizing part of this new fab’s capacity,” Huang said, adding that Powerchip intended to bridge
Microsoft Corp yesterday said that it would create Thailand’s first data center region to boost cloud and artificial intelligence (AI) infrastructure, promising AI training to more than 100,000 people to develop tech. Bangkok is a key economic player in Southeast Asia, but it has lagged behind Indonesia and Singapore when it comes to the tech industry. Thailand has an “incredible opportunity to build a digital-first, AI-powered future,” Microsoft chairman and chief executive officer Satya Nadella said at an event in Bangkok. Data center regions are physical locations that store computing infrastructure, allowing secure and reliable access to cloud platforms. The global embrace of AI
Qualcomm Inc, the world’s biggest seller of smartphone processors, gave an upbeat forecast for sales and profit in the current period, suggesting demand for handsets is increasing after a two-year slump. Revenue in the three months ended in June will be US$8.8 billion to US$9.6 billion, the company said in a statement Wednesday. Excluding certain items, earnings will be US$2.15 to US$2.35 a share. Analysts had projected sales of US$9.08 billion and earnings of US$2.16 a share. The outlook signals that the smartphone market has begun to bounce back, tracking with Qualcomm’s forecast that demand would gradually recover this year. The San